Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study

JACC-CARDIOVASCULAR IMAGING

卷:11

Article

Rivers, Joshua P.¹  Powell-Wiley, Tiffany M.¹  Dey, Amit K.¹  Rodante, Justin A.¹  Chung, Jonathan H.¹  Joshi, Aditya A.¹  Natarajan, Balaji¹  Sajja, Aparna P.¹  Chaturvedi, Abhishek¹  Rana, Anshuma¹  Harrington, Charlotte L.¹  Teague, Heather L.¹  Lockshin, Benjamin N.²  Ahlman, Mark A.³  Yao, Jianhua³  Playford, Martin P.¹  Gelfand, Joel M.⁴  Mehta, Nehal N.¹ 

[1] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA

[2] DermAssociates, Silver Spring, MD USA

[3] NIH, Dept Radiol & Imaging Sci, Clin Res Ctr, Bldg 10, Bethesda, MD 20892 USA

[4] Hosp Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA

关键词: cardiometabolic disease;    cardiovascular disease;    F-18-FDG PET/CT;    psoriasis;    vascular inflammation;    visceral adiposity;   

DOI  :  10.1016/j.jcmg.2017.08.014

来源: Elsevier

【 摘 要 】

OBJECTIVES The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by F-18-Fluorodeoxyglucose (F-18-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI. BACKGROUND PSO, a chronic inflammatory skin disease, is associated with VI by F-18-FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation. Recently, VI was associated with future cardiovascular events; however, the relationship of visceral and subcutaneous adiposity with VI in PSO has yet to be evaluated. METHODS Consecutive PSO patients (N = 77) underwent F-18-FDG PET/CT scans to measure VI and abdominal adiposity. A subset of PSO patients with severe skin disease was scanned at 1 year following PSO treatment (N = 13). RESULTS The cohort was middle aged (51.8 +/- 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (beta = 0.33; p = 0.004) beyond SAT (beta = 0.30; p = 0.005). VAT (beta = 0.55; p < 0.001), but not SAT (beta = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (beta = 0.53; p = 0.049). CONCLUSIONS Volume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO. Published by Elsevier on behalf of the American College of Cardiology Foundation.

【 授权许可】

Free